Vividion Therapeutics
Karl Bedke has worked as a Principal Scientist at Vividion Therapeutics since January 2020. Before that, they were a Scientist II at Peloton Therapeutics from August 2017 to January 2020. From July 2011 to July 2017, they worked as a Scientist at Amgen.
Karl Bedke obtained their Bachelor of Science (B.S.) degree in Chemistry from Brigham Young University between 1999 and 2006. Later, they pursued a Doctor of Philosophy (Ph.D.) degree in Organic Chemistry from UC Irvine, completing their studies between 2006 and 2011.
Vividion Therapeutics
2 followers
Vividion Therapeutics, Inc. is a biotechnology company focused on transforming the future of human health through the creation of highly selective small molecule medicines that drug traditionally inaccessible targets.